AstraZeneca on Monday announced it will halt a trial of Crestor earlier than scheduled after results showed the cholesterol-lowering drug had significant advantages over placebo. The study found Crestor effective in lowering the risk of major cardiovascular events in patients with high levels of C-reactive protein, which has been associated with heart problems.
A clinical trial for Novartis AG's Lotrel, a pill that combines two blood pressure drugs, was stopped early because it was shown to reduce heart attacks and strokes 20% more than an ACE inhibitor and diuretic combination. U.S. researchers said the findings may change guidelines for the way hypertension is treated.
A new Danish study has shown that diabetes patients have more than 2.4 times the regular risk of dying from cardiovascular disease, approximately the same as individuals who have had a heart attack. One researcher encouraged early primary prevention of cardiovascular diseases for diabetics.